[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ptosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ptosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100634034","a-prospective-cohort-study-on-visual-function-and-psychological-conditions-before-and-after-surgery-for-congenital-ptosis-100634034",false,"NCT07534436","A Prospective Cohort Study on Visual Function and Psychological Conditions Before and After Surgery for Congenital Ptosis","Inclusion Criteria:\n\n1. Unilateral or bilateral congenital ptosis, male or female;\n2. Age: 3-60 years old\n3. Informed consent, and voluntary signing of the informed consent form, in compliance with ethical norms\n\nExclusion Criteria:\n\n\\-",true,"ALL","3 Years","60 Years",{"count":20,"type":21},73,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to learn about the 6-month effects of Levator Resection combined with Fascial Sheath Suspension surgery in patients who undergo this procedure to treat congenital ptosis. The main questions it aims to answer are:\n\nDoes this combined surgery improve best-corrected visual acuity, stereopsis, and other visual function indicators in patients with congenital ptosis within 6 months after the operation?\n\nDoes this surgery lead to an improvement in patient-reported quality of life during the same period?\n\nPatients already scheduled to undergo this combined surgery as part of their regular medical care for congenital ptosis will complete a series of standardized ophthalmological examinations and a quality of life questionnaire before surgery and at 1, 3, and 6 months post-operation.",[26],"Ptosis","RECRUITING","2026-04-09",{"date":30,"type":31},"2026-04-16","ACTUAL",{"date":33,"type":31},"2025-06-01",{"date":35,"type":21},"2026-09-30",{"name":37,"class":38},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100363058","phase-4-the-effect-of-lumify-on-ocular-redness-intraocular-pressure-and-eyelid-position-in-glaucoma-patients-100363058","NCT04007276","The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of primary open angle glaucoma\n* Willing and able to give informed consent\n* Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use\n\nExclusion Criteria:\n\n* Pregnancy\n* Prisoners\n* Known allergy or sensitivities to brimonidine\n* No surgery within the past 6 months\n* No history of lid surgery or botox\n* Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator\n* Inability to sit comfortably for 30 minutes\n* Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study","18 Years",{"count":49,"type":21},60,"INTERVENTIONAL",[52],"PHASE4","Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.",[55,56,57,58,26,59],"Glaucoma","Glaucoma, Open-Angle","Glaucoma; Drugs","Droopy Eyelid","Glaucoma, Primary Open Angle","NOT_YET_RECRUITING","2025-09-30",{"date":63,"type":31},"2025-10-01",{"date":65,"type":21},"2026-11-10",{"date":67,"type":21},"2036-06-01",{"name":69,"class":38},"Tulane University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":5},"100496580","performance-and-safety-assessment-of-spring-thread-elastic-tensor-thread-in-patients-with-mild-to-moderate-facial-ptosis-100496580","NCT05746078","Performance and Safety Assessment of SPRING THREAD® Elastic Tensor Thread in Patients with Mild to Moderate Facial Ptosis.","Long-term Assessment of the Performance and Safety of SPRING THREAD® Elastic Tensor Thread.","ESTES","Inclusion Criteria:\n\n* Men \u002F women aged 35 to 75 with facial ptosis (cheekbones, jowls) with or without a history of aesthetic treatment (botox, filler, surgical lift).\n* Patient able to understand the explanations given.\n* Patient informed and not objecting to participate in the study.\n* Patient able to comply with protocol requirements, including follow-up visits.\n* Patient affiliated to social security.\n\nExclusion Criteria:\n\n* Patient unable to understand study information and attend study visits.\n* Patient did not give consent to participate.\n* Patients who have had a previous facial rejuvenation treatment in the 3 months prior to the study.\n* Patients treated with long-term systemic corticosteroids.\n* Patients with visceral failure, chronic immunological pathology, pregnant or breasfeading women.\n* Patient participating or having participated in another clinical trial protocol, drug or medical device within 30 days of inclusion.\n* Patient refusing to participate in the clinical investigation.","35 Years","75 Years",{"count":81,"type":21},99,"The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SPRING THREAD® elastic tensor thread. The study will evaluate the outcome of the SPRING THREAD® elastic tensor thread range over a period of 5 years.",[26,84],"Ptosis, Mild",[86],"Ptosis, Moderate","2024-12-09",{"date":89,"type":31},"2024-12-12",{"date":91,"type":31},"2023-02-16",{"date":93,"type":21},"2029-03",{"name":95,"class":96},"1st SurgiConcept","INDUSTRY"]